Sanofi (NASDAQ:SNY) Shares Sold by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC trimmed its holdings in Sanofi (NASDAQ:SNY) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 783,816 shares of the company’s stock after selling 2,780 shares during the period. Brandywine Global Investment Management LLC’s holdings in Sanofi were worth $37,803,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of SNY. Synergy Asset Management LLC purchased a new position in shares of Sanofi in the 4th quarter worth $25,000. McClarren Financial Advisors Inc. raised its holdings in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the period. Lee Danner & Bass Inc. acquired a new position in shares of Sanofi in the 4th quarter valued at about $31,000. Sunbelt Securities Inc. lifted its stake in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new position in Sanofi in the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Up 1.7 %

NASDAQ:SNY opened at $55.82 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a 50-day simple moving average of $55.13 and a 200 day simple moving average of $52.79. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a market capitalization of $141.66 billion, a price-to-earnings ratio of 22.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.